PNEUMOCOCCAL VACCINATION WITH 13-VALENT POLYSACCHARIDE CONJUGATE VACCINE FOR OLDER ADULTS WITH CHRONIC CONDITIONS: BUDGET IMPACT ANALYSIS IN COLOMBIA

被引：0
|
作者：
LaRotta, J. [1 ]
Sanchez, Reyes J. M. [2 ]
Gamboa, Castano N. [1 ]
机构：
[1] Pfizer SAS, Bogota, Colombia
[2] Pfizer SAS, Bogota, Cun, Colombia
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC103
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [21] Economic impact of 13-valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions
    Martikainen, Janne A.
    Soini, Erkki J.
    Laine, Juha
    Ahman, Heidi
    Postila, Ville
    Klemets, Peter
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2014, 20 (04) : 333 - 341
  • [22] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Jackson, Lisa A.
    Gurtman, Alejandra
    Rice, Kathryn
    Pauksens, Karlis
    Greenberg, Richard N.
    Jones, Thomas R.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3585 - 3593
  • [23] Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
    Shiramoto, Masanari
    Hanada, Ryuzo
    Juergens, Christine
    Shoji, Yasuko
    Yoshida, Mizuki
    Ballan, Barry
    Cooper, David
    Gruber, William C.
    Scott, Daniel A.
    Schmoele-Thoma, Beate
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (09) : 2198 - 2206
  • [24] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices
    Kaye, Donald
    CLINICAL INFECTIOUS DISEASES, 2013, 56 (01)
  • [25] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
    Masuda, Toshihiro
    Akamatsu, Taisuke
    Nakatani, Eiji
    Tamura, Kanami
    Takahashi, Shingo
    Tanaka, Yuko
    Watanabe, Hirofumi
    Endo, Yoshinari
    Suzuki, Takahito
    Noguchi, Rie
    Saigusa, Mika
    Yamamoto, Akito
    Shishido, Yuichiro
    Akita, Takefumi
    Morita, Satoru
    Asada, Kazuhiro
    Shirai, Toshihiro
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [26] 13-valent pneumococcal conjugate vaccine in Africa
    Cohen, Robert
    Levy, Corinne
    LANCET GLOBAL HEALTH, 2017, 5 (03): : E244 - E245
  • [27] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]Profile Report
    Sean T. Duggan
    Pediatric Drugs, 2012, 14 : 67 - 69
  • [28] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naive to pneumococcal vaccination
    Wysocki, Jacek
    Brzostek, Jerzy
    Szymanski, Henryk
    Tetiurka, Boguslaw
    Toporowska-Kowalska, Ewa
    Wasowska-Krolikowska, Krystyna
    Sarkozy, Denise A.
    Giardina, Peter C.
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    VACCINE, 2015, 33 (14) : 1719 - 1725
  • [29] Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®] Profile Report
    Duggan, Sean T.
    PEDIATRIC DRUGS, 2012, 14 (01) : 67 - 69
  • [30] Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Bennett, Nancy M.
    Whitney, Cynthia G.
    Moore, Matt
    Pilishvili, Tamara
    Dooling, Kathleen L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (01) : 232 - 235
12345